newsfilter
← Latest News
PR Newswire·

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

BIAFBIAFW
  • BioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) entered a definitive agreement with an institutional investor to sell common stock or pre-funded warrants at $6.122 per share ($6.115 per pre-funded warrant) in a registered direct offering priced at-the-market.
  • A concurrent private placement involves selling warrants to purchase up to 980,072 common shares at an exercise price of $6.122 per share.
  • Pre-funded warrants carry an exercise price of $0.007, while the new warrants are exercisable following stockholder approval & expire five years from that date.
  • WallachBeth Capital, LLC acts as the sole placement agent for the transaction.
  • Expected gross proceeds are approximately $4 million before deducting fees & expenses.
  • Proceeds will fund working capital, support sales growth for the CyPath® Lung test, & cover general corporate purposes.
  • The offering is conducted under a shelf registration statement on Form S-3 declared effective by the SEC on November 27, 2023.
  • Closing is anticipated on or about October 9, 2026, subject to customary conditions.